Rosetta Genomics And M. D. Anderson To Develop A MicroRN Based Diagnostic Test To Identify Risk Of Recurrence Of Lung Cancer

Rosetta Genomics, Ltd. (NASDQ: ROSG), a leader in the development of microRNA-based diagnostic and therapeutic products, announced a research collaboration with The University of Texas M. D. Anderson Cancer Center and the Kleberg Center for Molecular Markers to develop a microRNA- based diagnostic test to predict risk of disease recurrence in lung cancer patients who have undergone curative resection.

More: continued here

Filed under: Lung Cancer on June 10th, 2008